SRSF2 and myelodysplastic syndrome: Mutations in SRSF2 occur in about 10% of MDS cases and are observed together with neutropenia and pronounced thrombocytopenia, largely in patients with multilineage dysplasia and/or excess blasts and are prognostic of a high risk of AML and poor overall survival [42].